Acquisitions and Divestitures - Narrative (Bayer and Joint Venture Dissolution) (Details) ft² in Thousands, $ in Thousands			12 Months Ended
	Oct. 17, 2022 USD ($) ft² lease	Oct. 16, 2022 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Oct. 03, 2022
Business Acquisition [Line Items]
Equity method investments			$ 0	$ 1,543
Intangibles estimated useful life			15 years
General and administrative			$ 385,025	1,429,799	$ 862,952
Developed Technology
Business Acquisition [Line Items]
Intangibles estimated useful life						5 years
Joyn Bio
Business Acquisition [Line Items]
Gain on company's equity remeasurement				17,000
Equity method investments				0
Joyn Bio | Developed Technology
Business Acquisition [Line Items]
Intangibles estimated useful life			5 years
Bayer
Business Acquisition [Line Items]
Area of land | ft²	175
Bayer Acquisition and Joint Venture
Business Acquisition [Line Items]
Number of real estate leases | lease	2
Research and development process, term	3 years
Product support services, term	3 years
Proceeds from joint venture termination	$ 90,000
Payments for services and licenses, quarterly installments, term	3 years
Equity interest, percentage	50.00%
Gain on company's equity remeasurement				14,000
Business combination, equity interest in acquiree, fair value	$ 14,000
Business combination, consideration transferred, convertible promissory notes		$ 10,000
Promissory notes				4,800
Equity method investments				0
Gain on notes receivable				5,300
Outstanding principal and accrued interest				10,100
Dissolution expense			$ 200	3,000
General and administrative				$ 12,000
Bayer Acquisition and Joint Venture | Joyn Bio
Business Acquisition [Line Items]
Equity interest, percentage	50.00%
Business combination, equity interest in acquiree, fair value	$ 0